REYKJAVIK, ICELAND AND BURGDORF, SWITZERLAND (JULY 9, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the expansion of its capacity for assembly and packaging with the acquisition of Ivers-Lee Group (“Ivers-Lee”), a family owned business with headquarters in Burgdorf, Switzerland specializing in providing high-quality assembly and packaging services for the pharmaceutical sector. While I ...

REYKJAVIK, Iceland and BURGDORF, Switzerland, July 09, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the expansion of its capacity for assembly and packaging with the acquisition of Ivers-Lee Group (“Ivers-Lee”), a family owned business with headquarters in Burgdorf, Switzerland specializing in providing high-quality assembly and packaging services for the pharmaceutic ...

Core Viewpoint - Brady Corporation reported strong financial results for the third quarter of fiscal 2025, with significant sales growth driven by acquisitions and organic growth in the Americas and Asia regions, despite challenges from foreign currency translation [2][8]. Financial Results - Sales for the third quarter ended April 30, 2025, were $382.6 million, an increase of 11.4% from $343.4 million in the same quarter last year. This growth included organic sales growth of 1.6%, acquisition-related growth of 10.5%, and a decline of 0.7% due to foreign currency translation [2][4]. - For the nine-month period ended April 30, 2025, sales increased by 11.9% to $1.12 billion from $998.0 million in the same period last year, with organic growth of 2.6% and acquisition growth of 10.2% [5][7]. Income Metrics - Income before income taxes for the third quarter increased by 2.1% to $65.7 million compared to $64.4 million in the same quarter last year. Adjusted income before income taxes rose by 11.5% to $74.4 million [3][6]. - Net income for the third quarter was $52.3 million, up from $50.9 million in the same quarter last year. Adjusted net income increased to $58.8 million from $52.7 million [4][7]. Earnings Per Share - Earnings per diluted Class A Nonvoting Common Share for the third quarter was $1.09, compared to $1.05 in the same quarter last year, reflecting a 3.8% increase. Adjusted diluted EPS reached a record high of $1.22, up 11.9% from $1.09 [4][29]. Regional Performance - Sales in the Americas and Asia increased by 12.9%, with organic growth of 5.4%. In contrast, sales in Europe and Australia grew by 8.7%, but organic sales declined by 5.4% [2][5]. Shareholder Returns - The company returned $44.5 million to shareholders through dividends and share repurchases during the quarter, including repurchasing 476,000 shares for $33.2 million [8][9]. Fiscal Guidance - The company tightened its Adjusted Diluted EPS guidance for the fiscal year ending July 31, 2025, to a range of $4.48 to $4.63 per share, and updated GAAP earnings guidance to $3.95 to $4.10 per share [10][11].

PARSIPPANY, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three and six month periods ended March 31, 2025. "This quarter’s financial results were once again slightly ahead of our prior expectations, as our teams executed well, which included driving an acceleration in our free-cash flow generation, thereby allowing us to continue to repay debt and create additional balance sheet flex ...